Mosunetuzumab
Mosunetuzumab is a monoclonal antibody under investigation for the treatment of follicular lymphoma.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD20, CD3 (bispecific) |
| Clinical data | |
| Other names | BTCT4465A, RG7828 |
| Drug class | Antineoplastic |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6515H10031N1725O2025S43 |
| Molar mass | 146301.54 g·mol−1 |
Society and culture
Legal status
On 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for mosunetuzumab under the brand name Lunsumio, intended for the treatment of relapsed or refractory follicular lymphoma.[1] The applicant for this medicinal product is Roche Registration GmbH.[1]
Names
Mosunetuzumab is the international nonproprietary name (INN).[2]
References
- "Lunsumio: Pending EC decision". European Medicines Agency (EMA). 22 April 2022. Retrieved 22 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.
Further reading
- Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. (February 2022). "Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study". Journal of Clinical Oncology. 40 (5): 481–491. doi:10.1200/JCO.21.00931. PMC 8824395. PMID 34914545.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.